Advertisement

Re: Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS Exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA NGS and responds to osimertinib

Published:August 04, 2022DOI:https://doi.org/10.1016/j.ejca.2022.06.039
      Whilst not disagreeing with much of the factual content in the recently published letter by O'Sullivan et al. [
      • O'Sullivan H.
      • d'Arienzo P.D.
      • Yousaf N.
      • Cui W.
      • Popat S.
      Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib.
      ], we feel that their article fails to consider relevance in a wider clinical context whilst making unjustifiable comments/recommendations on the basis of a single (n = 1) and also atypical case report.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • O'Sullivan H.
        • d'Arienzo P.D.
        • Yousaf N.
        • Cui W.
        • Popat S.
        Inadequacy of PCR genotyping in advanced non-small cell lung cancer: EGFR L747_A755delinsSS exon 19 deletion is not detected by the real-time PCR IdyllaTM EGFR mutation test but is detected by ctDNA next generation sequencing and responds to osimertinib.
        Eur J Cancer. 2022; 166: 38-40
        • Moore D.A.
        • Balbi K.B.
        • Poskitt B.
        • Bennett P.
        Prevalence and breakdown of EGFR exon 20 driver mutations in routine NHS lung cancer diagnostic testing.
        J Clin Pathol. 2022; 75: 209-210
        • Moore D.A.
        • Balbi K.B.
        • Ingham A.
        • Arkenau H.T.
        • Bennett P.
        Analysis of a large cohort of non-small cell lung cancers submitted for somatic variant analysis demonstrates that targeted next-generation sequencing is fit for purpose as a molecular diagnostic assay in routine practice.
        J Clin Pathol. 2018; 71: 1001-1006
        • Grant J.
        • Stanley A.
        • Balbi K.
        • Gerrard G.
        • Bennett P.
        Performance evaluation of the Biocartis Idylla EGFR Mutation Test using pre-extracted DNA from a cohort of highly characterised mutation positive samples.
        J Clin Pathol. 2022; 75: 241-249
        • Finall A.
        • Davies G.
        • Jones T.
        • Emlyn G.
        • Huey H.
        • Mullard A.
        Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up.
        J Clin Pathol. 2021; : 207987
        • Moore D.
        • Maddox A.M.
        • Gillibrand R.
        • Medeiros F.
        Is the current strategy for stratifying patients for targeted therapy use in NSCLC really logical and sustainable? Results from a retrospective study suggest otherwise.
        Lung Cancer. 2019; 127 (2019): S22

      Linked Article